Subscribe

Well Lead Medical Co., Ltd. (603309.SS)

CNY12.36 +0.22 (+1.81%)
CN SHH Healthcare Medical - Instruments & Supplies
Address 47, Guomao Avenue South 511434
Guangzhou, CN
CEO Guangyuan Han
Website welllead.com.cn
IPO 2015-03-02
ISIN CNE1000021C2

Explore sections of this company profile

Description

Well Lead Medical Co., Ltd. specializes in the comprehensive process of researching, producing, and commercializing medical catheters. These essential devices serve critical applications in various fields such as anesthesia, urology, respiratory care, and hemodialysis. The company's product portfolio also extends to drainage, suction, and nutritional delivery systems. Its offerings are integral to hospital environments, supporting surgical operations, therapeutic interventions, and both emergency and routine clinical patient management. Founded in Guangzhou, China, in 2004, the firm boasts a significant global presence, distributing its solutions across key markets including China, North America, Europe, and Japan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY12.36 +0.22 (+1.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
-0.19
Float Shares
276.16M
Free Float %
94.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.40% -10.44% -9.00% -17.67% -9.00% -8.46% +3.07% -34.04% -3.49% -38.14% +45.84%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
12.36
DCF (Unlevered) 0.37 -97.0%
DCF (Levered) 17.66 +42.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.72
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +8.1% ★ Q1'26: +2.5% (vs Q1'25)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    -65.3% Q1'26: +5.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +3.6% Q1'26: -1.1% (vs Q1'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    +9.1% Q1'26: +21.5% (vs Q1'25)
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    +5.5% Q1'26: +13.4% (vs Q1'25)
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +0.4% Q1'26: -3.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    2.37× Q1'26: 1.82× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.17) × ERP
WACC = 87% × Ke + 13% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.37 Current price: 12.36
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
548.87M
est: 560.00M (-2.0%)
515.42M
est: 639.00M (-19.3%)
629.89M
est: 560.00M (+12.5%)
745.83M
est: 639.00M (+16.7%)
993.81M
est: 735.00M (+35.2%)
1.12B
est: 1.19B (-5.9%)
1.36B
est: 1.42B (-3.7%)
1.39B
est: 1.36B (+1.7%)
1.51B
est: 1.54B (-2.1%)
1.63B
est: 1.74B (-6.0%)
1.84B
1.84B – 1.84B
+5.9% YoY
2.10B
2.09B – 2.10B
+14.2% YoY
2.40B
2.40B – 2.41B
+14.5% YoY
EBITDA
118.14M
est: 119.80M (-1.4%)
114.13M
est: 136.70M (-16.5%)
102.15M
est: 119.80M (-14.7%)
100.61M
est: 136.70M (-26.4%)
204.51M
est: 157.23M (+30.1%)
198.03M
est: 254.36M (-22.1%)
269.85M
est: 302.81M (-10.9%)
309.59M
est: 291.79M (+6.1%)
338.29M
est: 298.79M (+13.2%)
239.20M
est: 336.18M (-28.8%)
355.95M
355.77M – 356.12M
+5.9% YoY
406.52M
405.66M – 407.38M
+14.2% YoY
465.62M
464.98M – 466.26M
+14.5% YoY
EBIT
101.18M
est: 92.34M (+9.6%)
95.21M
est: 105.36M (-9.6%)
80.55M
est: 92.34M (-12.8%)
71.70M
est: 105.36M (-31.9%)
161.93M
est: 121.19M (+33.6%)
148.71M
est: 196.05M (-24.1%)
213.52M
est: 233.40M (-8.5%)
246.43M
est: 224.91M (+9.6%)
275.89M
est: 228.51M (+20.7%)
148.47M
est: 257.11M (-42.3%)
272.22M
272.09M – 272.36M
+5.9% YoY
310.90M
310.24M – 311.56M
+14.2% YoY
356.10M
355.61M – 356.59M
+14.5% YoY
Net Income
91.32M
est: 100.36M (-9.0%)
79.25M
est: 115.21M (-31.2%)
64.56M
est: 100.36M (-35.7%)
65.40M
est: 115.21M (-43.2%)
121.14M
est: 126.24M (-4.0%)
106.09M
est: 140.41M (-24.4%)
166.57M
est: 162.35M (+2.6%)
192.49M
est: 190.14M (+1.2%)
219.39M
est: 220.18M (-0.4%)
76.33M
est: 264.21M (-71.1%)
268.61M
268.14M – 269.09M
+1.7% YoY
318.52M
317.95M – 319.09M
+18.6% YoY
381.64M
380.96M – 382.32M
+19.8% YoY
SGA
96.64M
est: 59.69M (+61.9%)
114.96M
est: 68.11M (+68.8%)
116.54M
est: 59.69M (+95.2%)
166.28M
est: 68.11M (+144.1%)
232.29M
est: 78.35M (+196.5%)
255.29M
est: 126.74M (+101.4%)
285.27M
est: 150.89M (+89.1%)
287.80M
est: 145.40M (+97.9%)
282.93M
est: 274.75M (+3.0%)
95.58M
est: 309.14M (-69.1%)
327.32M
327.16M – 327.48M
+5.9% YoY
373.82M
373.03M – 374.61M
+14.2% YoY
428.17M
427.58M – 428.75M
+14.5% YoY
EPS
0.37
est: 0.34 (+7.8%)
0.31
est: 0.39 (-21.3%)
0.25
est: 0.34 (-27.1%)
0.25
est: 0.39 (-36.5%)
0.47
est: 0.43 (+8.9%)
0.41
est: 0.48 (-14.6%)
0.57
est: 0.56 (+2.7%)
0.66
est: 0.65 (+1.5%)
0.75
est: 0.75 (+0.0%)
0.26
est: 0.90 (-71.1%)
0.92
0.91 – 0.92
+1.7% YoY
1.09
1.08 – 1.09
+18.6% YoY
1.30
1.30 – 1.30
+19.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-28 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-27 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-26 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-25 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-22 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-21 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-20 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-19 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-18 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-15 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-14 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-13 B 3/5 4/5 3/5 4/5 2/5 1/5 3/5
2026-05-12 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-11 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-08 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-07 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-05-06 B 3/5 3/5 3/5 4/5 2/5 1/5 3/5
2026-04-30 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-29 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-28 B- 3/5 3/5 2/5 4/5 2/5 1/5 3/5
2026-04-27 B- 2/5 3/5 2/5 4/5 1/5 1/5 3/5
2026-04-24 B- 2/5 3/5 2/5 4/5 1/5 1/5 3/5
2026-04-23 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5
2026-04-22 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5
2026-04-21 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5
2026-04-20 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5
2026-04-17 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5
2026-04-16 A- 4/5 4/5 4/5 5/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
89.36M
OE per share TTM
0.31
Owner's Yield
2.52%
Maintenance CapEx ratio
113.14%
Maint CapEx / Avg PPE
48.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
56.6K
Shares Outstanding
291.87M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Bin Chen Deputy GM & Board Secretary — male
Guangyuan Han Vice Chairman & GM — male
Song Feng Duan Deputy GM & Director — male
Yimin Zhu Chief Financial Officer & Accounting Supervisor — female
Yungui Chen Deputy GM & Director — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies